Agronomics（V77）株式概要アグロノミクス・リミテッドは、エマージング・グロース、シード／スタートアップ、アーリーベンチャー、シリーズB、グロース・キャピタル投資を専門とするプライベート・エクイティおよびベンチャー・キャピタル企業である。 詳細V77 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間51.2%減少しました。 収益が 100 万ドル未満 ( £-12M )German市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( €82M )すべてのリスクチェックを見るV77 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.065該当なし内在価値ディスカウントEst. Revenue$PastFuture-17m24m2016201920222025202620282031Revenue UK£0.04Earnings UK£0.01AdvancedSet Fair ValueView all narrativesAgronomics Limited 競合他社Mountain AllianceSymbol: XTRA:ECFMarket cap: €21.0mBlue CapSymbol: XTRA:B7EMarket cap: €87.3mSPARTA InvestSymbol: DUSE:F35Market cap: €148.5mEight Capital PartnersSymbol: DB:ECS0Market cap: €25.3m価格と性能株価の高値、安値、推移の概要Agronomics過去の株価現在の株価UK£0.06552週高値UK£0.1252週安値UK£0.04ベータ0.921ヶ月の変化-17.72%3ヶ月変化-24.42%1年変化n/a3年間の変化-58.06%5年間の変化n/aIPOからの変化-72.75%最新ニュースRecent Insider Transactions • Mar 15Co-Founder & Executive Chairperson recently bought €268k worth of stockOn the 12th of March, James Mellon bought around 3m shares on-market at roughly €0.081 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €432k worth in shares.Recent Insider Transactions • Feb 26Co-Founder & Executive Chairperson recently bought €76k worth of stockOn the 25th of February, James Mellon bought around 990k shares on-market at roughly €0.076 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €118k worth in shares.お知らせ • Dec 30Agronomics Limited, Annual General Meeting, Feb 13, 2026Agronomics Limited, Annual General Meeting, Feb 13, 2026. Location: the sanderson suite, claremont hotel, loch promenade, douglas im1 2lx Isle of ManBuy Or Sell Opportunity • Dec 05Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €0.067. The fair value is estimated to be €0.088, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Nov 19Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.074. The fair value is estimated to be €0.095, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making.New Risk • Aug 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.1m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$99.1m).最新情報をもっと見るRecent updatesRecent Insider Transactions • Mar 15Co-Founder & Executive Chairperson recently bought €268k worth of stockOn the 12th of March, James Mellon bought around 3m shares on-market at roughly €0.081 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €432k worth in shares.Recent Insider Transactions • Feb 26Co-Founder & Executive Chairperson recently bought €76k worth of stockOn the 25th of February, James Mellon bought around 990k shares on-market at roughly €0.076 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €118k worth in shares.お知らせ • Dec 30Agronomics Limited, Annual General Meeting, Feb 13, 2026Agronomics Limited, Annual General Meeting, Feb 13, 2026. Location: the sanderson suite, claremont hotel, loch promenade, douglas im1 2lx Isle of ManBuy Or Sell Opportunity • Dec 05Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €0.067. The fair value is estimated to be €0.088, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Nov 19Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.074. The fair value is estimated to be €0.095, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making.New Risk • Aug 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.1m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$99.1m).New Risk • Mar 15New major risk - Revenue and earnings growthEarnings have declined by 8.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€82.2m market cap, or US$89.4m).Recent Insider Transactions • Feb 07Co-Founder & Executive Chairperson recently bought €59k worth of stockOn the 4th of February, James Mellon bought around 1m shares on-market at roughly €0.046 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €234k worth in shares.お知らせ • Dec 28Agronomics Limited, Annual General Meeting, Feb 07, 2025Agronomics Limited, Annual General Meeting, Feb 07, 2025. Location: the sanderson suite, claremont hotel, loch promenade, im1 2lx, douglas Isle of ManNew Risk • Dec 25New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€46.6m market cap, or US$48.4m).Recent Insider Transactions • Oct 15Co-Founder & Executive Chairperson recently bought €115k worth of stockOn the 7th of October, James Mellon bought around 2m shares on-market at roughly €0.058 per share. This transaction amounted to 43% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €174k worth in shares.New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€68.4m market cap, or US$75.6m).New Risk • May 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.2m (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€90.2m market cap, or US$97.5m).New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.7m (US$94.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€88.7m market cap, or US$94.4m).お知らせ • Mar 15Umami Meats Pte. Ltd. acquired Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others.Umami Meats Pte. Ltd. acquired Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others on March 13, 2024. Umami acquired Shiok Meats in share-for-share transaction. As a result of this transaction, Agronomics now holds an equity ownership of 0.71% in UMAMI Bioworks on a fully diluted basis. Subject to audit, this position will be carried forward at a book value of £0.378 million. James Biddle and Roland Cornish of Beaumont Cornish Limited acted as Financial advisor in transaction. Umami Meats Pte. Ltd. completed the acquisition of Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others on March 13, 2024お知らせ • Jan 18Agronomics Limited Announces IsraFirst Regulatory Approval for Cultivated BeefAgronomics Ltd. announced that the Israeli Ministry of Health (IMOH) has granted regulatory approval for the world's first commercial sale of cultivated beef. Agronomics would like to congratulate Aleph Farms on becoming the first company in the world to gain regulatory approval for its cultivated beef product after the IMOH issued a 'no questions' letter, which allows the company to commercialise its products in Israel. Aleph Farms has also filed for regulatory approval in Singapore, Switzerland, the UK and the US, and is advancing its applications in other markets. Agronomics is aware of multiple companies, including those within its portfolio, that are expecting regulatory approval for cultivated meat and seafood products across several markets. Meanwhile, Vow Food is in the middle of a consultation process after its cultured quail was cleared as safe to eat by Food Standards Australia and New Zealand in December 2023. These announcements follow Upside Foods and Good Meat, which received regulatory approval for their cultivated chicken products in the US last year.New Risk • Dec 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 75% Last year net profit margin: 130% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Profit margins are more than 30% lower than last year (75% net profit margin).お知らせ • Dec 27Agronomics Limited, Annual General Meeting, Feb 08, 2024Agronomics Limited, Annual General Meeting, Feb 08, 2024, at 10:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel, Loch Promenade Douglas Isle of Manお知らせ • Dec 14Agronomics Limited appoints Jim Mellon as Executive Chairperson of the Board of Directors, 14 December 2023Agronomics Limited announced that it has appointed Jim Mellon as Executive Chairperson of the Board of Directors, effective 14 December 2023. Jim Mellon, formerly an Executive Director, succeeds Richard Reed in the role of Chair, with Richard Reed continuing to serve as an Independent Non-Executive Director of the Board.お知らせ • Sep 23Agronomics Limited (AIM:ANIC) announces an Equity Buyback for £3 million worth of its shares.Agronomics Limited (AIM:ANIC) announces a share repurchase program. Under the program, the company will repurchase up to £3 million worth of its shares. The maximum price to be paid for repurchase is the higher of the price of the last independent trade and the highest current independent purchase bid on the trading venue where the purchase is carried out and no share shall be bought back by the Company at a price per share higher than 75% of the last reported NAV Per Share published in the Company's most recent Quarterly NAV Statement. The purpose of the program is to reduce the share capital of the company. The repurchased shares will be cancelled unless used to cover obligations under share-based remuneration arrangements. The program will be valid till March 29, 2024. As of September 22, 2023, the company had 993,153,870 issued shares.New Risk • Aug 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).Recent Insider Transactions • May 12Executive Director recently bought €52k worth of stockOn the 5th of May, James Mellon bought around 392k shares on-market at roughly €0.13 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €79k. Insiders have collectively bought €137k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Mar 29Executive Director recently bought €79k worth of stockOn the 27th of March, James Mellon bought around 666k shares on-market at roughly €0.12 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €85k more in shares than they have sold in the last 12 months.お知らせ • Dec 21Agronomics Limited, Annual General Meeting, Feb 02, 2023Agronomics Limited, Annual General Meeting, Feb 02, 2023, at 10:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel Loch Promenade Douglas Isle of ManBoard Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director David Giampaolo was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director David Giampaolo was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director David Giampaolo was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元V77DE Capital MarketsDE 市場7D28.7%4.4%3.2%1Yn/a4.5%2.5%株主還元を見る業界別リターン: V77がGerman Capital Markets業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: V77 German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is V77's price volatile compared to industry and market?V77 volatilityV77 Average Weekly Movement34.9%Capital Markets Industry Average Movement5.0%Market Average Movement6.1%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: V77の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: V77の weekly volatility ( 35% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2011n/an/awww.agronomics.imアグロノミクス・リミテッドは、エマージング・グロース、シード／スタートアップ、アーリーベンチャー、シリーズB、グロース・キャピタル投資を専門とするプライベート・エクイティ／ベンチャー・キャピタル企業である。上場企業、非上場企業への投資を行う。細胞農業、培養肉、テクノロジー、現代食品・素材の新興産業、バイオ医薬品部門に重点を置いた代替タンパク質企業への投資を好み、バイオテクノロジーおよびバイオ医薬品企業への投資ポートフォリオを構築する予定である。また、バイオ・ファーマ・セクターへのエクスポージャーを持つ集団投資スキームの株式や、バイオ・ファーマ・セクター証券および／またはバイオ・ファーマ・セクターに関連するインデックスを原資産とする長期株式先取り証券への投資も行う。投資先企業へのマイノリティ投資を行う。バイオファーマ・セクターの債券に投資することもあるが、その場合、投資額は企業の純資産総額の15％を超えてはならない。バランスシート資本からの投資を好む。アグロノミクス・リミテッドは2011年5月3日に設立され、マン島のラムゼーに拠点を置く。もっと見るAgronomics Limited 基礎のまとめAgronomics の収益と売上を時価総額と比較するとどうか。V77 基礎統計学時価総額€81.98m収益（TTM）-€18.74m売上高(TTM)n/a-5.8xP/Sレシオ-4.4xPER（株価収益率V77 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計V77 損益計算書（TTM）収益-UK£12.14m売上原価UK£0売上総利益-UK£12.14mその他の費用UK£4.04m収益-UK£16.18m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.015グロス・マージン100.00%純利益率133.30%有利子負債／自己資本比率0%V77 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 14:22終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Agronomics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Alexander BrooksCanaccord Genuity
Recent Insider Transactions • Mar 15Co-Founder & Executive Chairperson recently bought €268k worth of stockOn the 12th of March, James Mellon bought around 3m shares on-market at roughly €0.081 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €432k worth in shares.
Recent Insider Transactions • Feb 26Co-Founder & Executive Chairperson recently bought €76k worth of stockOn the 25th of February, James Mellon bought around 990k shares on-market at roughly €0.076 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €118k worth in shares.
お知らせ • Dec 30Agronomics Limited, Annual General Meeting, Feb 13, 2026Agronomics Limited, Annual General Meeting, Feb 13, 2026. Location: the sanderson suite, claremont hotel, loch promenade, douglas im1 2lx Isle of Man
Buy Or Sell Opportunity • Dec 05Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €0.067. The fair value is estimated to be €0.088, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Nov 19Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.074. The fair value is estimated to be €0.095, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Aug 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.1m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$99.1m).
Recent Insider Transactions • Mar 15Co-Founder & Executive Chairperson recently bought €268k worth of stockOn the 12th of March, James Mellon bought around 3m shares on-market at roughly €0.081 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €432k worth in shares.
Recent Insider Transactions • Feb 26Co-Founder & Executive Chairperson recently bought €76k worth of stockOn the 25th of February, James Mellon bought around 990k shares on-market at roughly €0.076 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €118k worth in shares.
お知らせ • Dec 30Agronomics Limited, Annual General Meeting, Feb 13, 2026Agronomics Limited, Annual General Meeting, Feb 13, 2026. Location: the sanderson suite, claremont hotel, loch promenade, douglas im1 2lx Isle of Man
Buy Or Sell Opportunity • Dec 05Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €0.067. The fair value is estimated to be €0.088, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Nov 19Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.074. The fair value is estimated to be €0.095, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Aug 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.1m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$99.1m).
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings have declined by 8.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€82.2m market cap, or US$89.4m).
Recent Insider Transactions • Feb 07Co-Founder & Executive Chairperson recently bought €59k worth of stockOn the 4th of February, James Mellon bought around 1m shares on-market at roughly €0.046 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €234k worth in shares.
お知らせ • Dec 28Agronomics Limited, Annual General Meeting, Feb 07, 2025Agronomics Limited, Annual General Meeting, Feb 07, 2025. Location: the sanderson suite, claremont hotel, loch promenade, im1 2lx, douglas Isle of Man
New Risk • Dec 25New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€46.6m market cap, or US$48.4m).
Recent Insider Transactions • Oct 15Co-Founder & Executive Chairperson recently bought €115k worth of stockOn the 7th of October, James Mellon bought around 2m shares on-market at roughly €0.058 per share. This transaction amounted to 43% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €174k worth in shares.
New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€68.4m market cap, or US$75.6m).
New Risk • May 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.2m (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€90.2m market cap, or US$97.5m).
New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.7m (US$94.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€88.7m market cap, or US$94.4m).
お知らせ • Mar 15Umami Meats Pte. Ltd. acquired Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others.Umami Meats Pte. Ltd. acquired Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others on March 13, 2024. Umami acquired Shiok Meats in share-for-share transaction. As a result of this transaction, Agronomics now holds an equity ownership of 0.71% in UMAMI Bioworks on a fully diluted basis. Subject to audit, this position will be carried forward at a book value of £0.378 million. James Biddle and Roland Cornish of Beaumont Cornish Limited acted as Financial advisor in transaction. Umami Meats Pte. Ltd. completed the acquisition of Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others on March 13, 2024
お知らせ • Jan 18Agronomics Limited Announces IsraFirst Regulatory Approval for Cultivated BeefAgronomics Ltd. announced that the Israeli Ministry of Health (IMOH) has granted regulatory approval for the world's first commercial sale of cultivated beef. Agronomics would like to congratulate Aleph Farms on becoming the first company in the world to gain regulatory approval for its cultivated beef product after the IMOH issued a 'no questions' letter, which allows the company to commercialise its products in Israel. Aleph Farms has also filed for regulatory approval in Singapore, Switzerland, the UK and the US, and is advancing its applications in other markets. Agronomics is aware of multiple companies, including those within its portfolio, that are expecting regulatory approval for cultivated meat and seafood products across several markets. Meanwhile, Vow Food is in the middle of a consultation process after its cultured quail was cleared as safe to eat by Food Standards Australia and New Zealand in December 2023. These announcements follow Upside Foods and Good Meat, which received regulatory approval for their cultivated chicken products in the US last year.
New Risk • Dec 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 75% Last year net profit margin: 130% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Profit margins are more than 30% lower than last year (75% net profit margin).
お知らせ • Dec 27Agronomics Limited, Annual General Meeting, Feb 08, 2024Agronomics Limited, Annual General Meeting, Feb 08, 2024, at 10:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel, Loch Promenade Douglas Isle of Man
お知らせ • Dec 14Agronomics Limited appoints Jim Mellon as Executive Chairperson of the Board of Directors, 14 December 2023Agronomics Limited announced that it has appointed Jim Mellon as Executive Chairperson of the Board of Directors, effective 14 December 2023. Jim Mellon, formerly an Executive Director, succeeds Richard Reed in the role of Chair, with Richard Reed continuing to serve as an Independent Non-Executive Director of the Board.
お知らせ • Sep 23Agronomics Limited (AIM:ANIC) announces an Equity Buyback for £3 million worth of its shares.Agronomics Limited (AIM:ANIC) announces a share repurchase program. Under the program, the company will repurchase up to £3 million worth of its shares. The maximum price to be paid for repurchase is the higher of the price of the last independent trade and the highest current independent purchase bid on the trading venue where the purchase is carried out and no share shall be bought back by the Company at a price per share higher than 75% of the last reported NAV Per Share published in the Company's most recent Quarterly NAV Statement. The purpose of the program is to reduce the share capital of the company. The repurchased shares will be cancelled unless used to cover obligations under share-based remuneration arrangements. The program will be valid till March 29, 2024. As of September 22, 2023, the company had 993,153,870 issued shares.
New Risk • Aug 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
Recent Insider Transactions • May 12Executive Director recently bought €52k worth of stockOn the 5th of May, James Mellon bought around 392k shares on-market at roughly €0.13 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €79k. Insiders have collectively bought €137k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Mar 29Executive Director recently bought €79k worth of stockOn the 27th of March, James Mellon bought around 666k shares on-market at roughly €0.12 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €85k more in shares than they have sold in the last 12 months.
お知らせ • Dec 21Agronomics Limited, Annual General Meeting, Feb 02, 2023Agronomics Limited, Annual General Meeting, Feb 02, 2023, at 10:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel Loch Promenade Douglas Isle of Man
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director David Giampaolo was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director David Giampaolo was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director David Giampaolo was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
